Atamyo Therapeutics receives IND for ATA-100, a Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) Posted on September 7, 2023September 29, 2023 By admin Find out more! Post navigation Previous: AskBio Announces First Patient Dosed in Phase 1 / Phase 2 Trial of AB-1003 Gene Therapy for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)Next: LGMD Awareness Day is September 30th! admin Learn More →
